Beta Bionics (BBNX) Chief Product Officer reports 2,200-share 10b5-1 sale

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a planned sale of company stock. On January 6, 2026, he sold 2,200 shares of common stock at a weighted average price of $30.1005 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owned 80,752 shares of Beta Bionics common stock directly. The filing notes that individual sale prices ranged between $30.00 and $30.13, and detailed breakdowns are available to regulators, the company, or its security holders on request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		2,200	D	$30.1005(2)	80,752	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

2. The weighted average sale price for the transaction reported was $30.1005 and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading Beta Bionics (BBNX) stock in this Form 4?

The insider is Mike Mensinger, who serves as Chief Product Officer of Beta Bionics, Inc. and is a reporting person for this transaction.

How many Beta Bionics (BBNX) shares did the Chief Product Officer sell?

On January 6, 2026, Chief Product Officer Mike Mensinger sold 2,200 shares of common stock of Beta Bionics, Inc..

At what price were the Beta Bionics (BBNX) shares sold in this Form 4 filing?

The weighted average sale price was $30.1005 per share, with individual sale prices ranging from $30.00 to $30.13 for the reported transaction.

Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the 2,200-share sale was made under a Rule 10b5-1 Plan that was adopted on September 8, 2025.

How many Beta Bionics (BBNX) shares does the insider hold after this transaction?

Following the reported sale, Mike Mensinger beneficially owned 80,752 shares of Beta Bionics common stock in direct ownership.

Is the Beta Bionics (BBNX) insider ownership direct or indirect in this Form 4?

The Form 4 reports the 80,752 shares held by Mike Mensinger as direct (D) ownership, with no indirect ownership noted in the excerpt.